Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating VB-201 for efficacy and safety in severe COVID-19 patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome Coronavirus 2 Infection

Drugs mentioned

• VB-201

Snippet

Sponsor: Vascular Biogenics Ltd. operating as VBL Therapeutics | Conditions: Severe COVID-19 | Phase 2 | Status: COMPLETED